CDSCO panel recommends emergency use nod for SII Covovax for kids aged 7 to 11 years
The recommendation has been sent to Drugs Controller General of India (DCGI) for final approval.;
New Delhi: An expert panel of India's central drug authority on Friday recommended granting emergency use authorisation to Serum Institute's Covovax for children aged 7 to 11 years, official sources said.
The recommendation has been sent to Drugs Controller General of India (DCGI) for final approval.
The application for emergency use authorisation was submitted by Prakash Kumar Singh, director (government and regulatory affairs) at Serum Institute of India (SII) on March 16.
"The Subject Expert Committee (SEC) on COVID-19 of the CDSCO deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years," an official source said.
The expert panel in its last meeting in April had sought more data from the Pune-based firm over the application.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.